Hikma Pharmaceuticals Share News (HIK)

Hikma's Siggi Olafsson stands down as CEO

(Sharecast News) - Drugmaker Hikma Pharmaceuticals revealed on Tuesday that chief executive Siggi Olafsson has resigned from both the role and the company's board of directors in order to pursue other opportunities.

UK shareholder meetings calendar - next 7 days

LONDON BROKER RATINGS: Downgrades for Centrica and Rathbones

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

LONDON MARKET MIDDAY: Pound slips as BoE opts for quarter-point hike

(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point.

Signs of slowdown on the continent

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

SIGNS OF SLOWDOWN ON THE CONTINENT (1051 GMT)

TOP NEWS: Hikma shares fall 10% on delay to Jazz Pharmaceuticals drug

(Alliance News) - Shares in Hikma Pharmaceuticals PLC fell early Thursday, after the drugmaker downgraded guidance for its Generics business due to the delayed launch of a generic of the Xyrem treatment for narcolepsy.

LONDON MARKET OPEN: Mondi and Shell lift FTSE 100 after strong updates

(Alliance News) - Stock prices in London opened sharply higher on Thursday after the US Federal reserve assuaged fears over further aggressive monetary policy tightening, while positive updates from Mondi and Shell boosted the FTSE 100.

Hikma cuts 2022 generics guidance due to drug launch delay

(Sharecast News) - Hikma Pharmaceuticals cut guidance for its generics business on Thursday, citing a delay to a drug launch.

IN BRIEF: Hikma says has not entered license agreement with Opiant

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.

LONDON MARKET CLOSE: Stocks end volatile April on high note

(Alliance News) - Stocks in London on Friday ended a volatile month of April in a positive fashion, amid a continued rush of company earnings, while markets in the US sank as high-profile tech names disappointed.

Hikma Pharmaceuticals notes "slow" start for Generics business in 2022

(Alliance News) - Hikma Pharmaceuticals PLC said on Friday that both its Injectables and Branded businesses have performed well at the start of the year but noted its Generics business has experienced some headwinds.

Hikma shares fall as generics unit faces headwinds

(Sharecast News) - Hikma Pharmaceuticals shares fell as the company reported headwinds at its generics business.

LONDON BRIEFING: Pearson has positive first quarter, buys language app

(Alliance News) - Educational materials publisher Pearson on Friday provided a positive update on first quarter trading, while also announcing a new acquisition.

UK dividends calendar - next 7 days

IN BRIEF: Hikma Pharmaceuticals completes Custopharm deal

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to USD425 million. Deal will add up to 13 approved products and additional pipeline products.